Economic value of Acinetobacter baumannii screening in the intensive care unit  by Lee, B.Y. et al.
Economic value of Acinetobacter baumannii screening in the intensive
care unit
B. Y. Lee1,2, S. M. McGlone1,2, Y. Doi3, R. R. Bailey1,2 and L. H. Harrison4
1) Public Health Computational and Operations Research, 2) Graduate School of Public Health, 3) Division of Infectious Diseases, School of Medicine and
4) Infectious Disease Epidemiology Research Unit, School of Medicine and Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
Abstract
Although Acinetobacter baumannii (A. baumannii) is an increasingly common nosocomial pathogen that can cause serious infections in the
intensive care unit (ICU), most ICUs do not actively screen admissions for this pathogen. We developed an economic computer simula-
tion model to determine the potential cost-consequences to the hospital of implementing routine A. baumannii screening of ICU admis-
sions and isolating those patients who tested positive, comparing two screening methods, sponge and swab, with each other and no
screening. Sensitivity analyses varied the colonization prevalence, percentage of colonized individuals who had active A. baumannii infec-
tions, A. baumannii reproductive rate (R), and contact isolation efﬁcacy. Both screening methods were cost-effective for almost all sce-
narios tested, yielding cost-savings ranging from )$1 to )$1563. Sponge screening was not cost-saving when colonization prevalence
was £1%, probability of infection £30%, R £ 0.25, and contact isolation efﬁcacy £25%. Swab screening was not cost-saving under these
same conditions when the probability of infection was £40%. Sponge screening tended to be more cost-saving than swab screening
(additional savings ranged from $1 to $421). Routine A. baumannii screening of ICU patients may save costs for hospitals.
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Introduction
Acinetobacter baumannii (A. baumannii) is one of the most chal-
lenging Gram-negative pathogens to control and treat in the
intensive care unit (ICU) [1], resulting in substantial morbidity
and costs [2–7]. A. baumannii causes serious infections in
critically ill patients, extending their length of stay (LOS) [2,4,8–
11]. This infection is becoming increasingly common worldwide
[1,4,12–14]. Isolating or cohorting A. baumannii carriers
remains the main measure to prevent its spread [15,16].
Currently, most hospitals do not perform active surveil-
lance of A. baumannii; those that do may differ in screening
methods. Studies have shown that active surveillance (i.e.
testing patients and either isolating or decolonizing those
who test positive) may be a cost-effective means of controlling
methicillin-resistant Staphylococcus aureus (MRSA) [17–20].
The most common A. baumannii surveillance strategy consists
of swabbing various anatomical sites (e.g. forehead, nasal cav-
ity, pharynx, buccal mucosa, wounds, axilla and groin), an
approach that has relatively low reported sensitivities
(13.5–52.2% at single sites and 55.0–77.8% for multiple sites)
[15,16]. We recently reported a new surveillance strategy that
uses a sponge to wipe down a patient’s upper arm and thigh,
resulting in a higher sensitivity (88.9–89.1%) [15]. To determine
the potential economic value of screening all ICU admissions
for A. baumannii, we developed a computer simulation model.
Sensitivity analyses varied the probabilities of A. baumannii
colonization, infection, LOS and reproductive rate (R, the
number of new cases one infectious individual generates).
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Methods
This study further developed a previously published TreeAge
Pro 2009 (TreeAge Suite, Williamstown, MA, USA) decision
analytical computer model [3]. Our model sought to deter-
mine the potential economic value of screening patients for
A. baumannii upon ICU entrance from the hospital perspec-
tive. Fig. 1 shows the model’s general structure. Patients
could undergo screening by sponge, screening by swab, or
no screening. Positive tests led to contact isolation of the
patient (use of gloves and gowns upon patient contact).
Colonized patients could transmit A. baumannii to others
based on R. For patients in contact isolation, the efﬁcacy of
contact isolation attenuated transmission.
Each primary and secondary colonized case had a proba-
bility of remaining asymptomatic or developing clinical A. bau-
mannii infection. Clinical infection led to a LOS based on an
extensive literature search described in our previous paper
[3], which only included those studies that measured LOS
after A. baumannii diagnosis and adequately matched control
subjects based on severity of illness and co-morbidities (i.e.
used measures such as the Acute Physiology Index, McCabe
Score, and Charlson Co-morbidity Index) [5,11,21]. Coloni-
zation did not affect a patient’s LOS; those who were non-
carriers or only colonized, had a stay 0.53 times that of
A. baumannii-infected patients.
Increased LOS translated into lost bed days (i.e. opportu-
nity cost for a hospital or lost revenue due to A. baumannii
patients occupying beds that could have been used by other
patients, as described by Graves) [22].
Each screening strategy had accompanying sensitivities; the
speciﬁcity of each test was assumed to be the same as
A. baumannii is not commensal and all samples were pro-
cessed on the same media (modiﬁed Leeds Acinetobacter
medium (mLAM)). Speciﬁcity was high (98–100%), as actual
growth of A. baumannii from specimens is considered the ref-
erence standard for identiﬁcation. mLAM is a selective med-
ium for culturing Acinetobacter spp. that has been modiﬁed
with the addition of aztreonam 2 lg/mL or ceftazidine 4 lg/
mL so as to only detect isolates with resistance to three or
more drug classes [15]. This medium reduces the time
needed for the technician to read the results because it is
not necessary to investigate non-Acinetobacter colonies.
Sponge testing
Swab testing
No testing
Contact
isolation
Generate r*
secondary
cases
Positive test (TP)
Negative test (FN)
A. baumannii
Generate r
secondary
cases
A. baumannii infection
No A. baumannii
Positive test (FP)
Negative test (TN)
No A. baumannii infection
A. baumannii infection
No A. baumannii infection
Contact
isolation
Contact
isolation
Generate r*
secondary
cases
Positive test (TP)
Negative test (FN)
A. baumannii
Generate r
secondary
cases
A. baumannii infection
No A. baumannii
Positive test (FP)
Negative test (TN)
No A. baumannii infection
A. baumannii infection
No A. baumannii infection
Contact
isolation
Generate r
secondary
cases
A. baumannii infection
No A. baumannii infection
A. baumannii
No A. baumannii
r = reproductive rate
*r is reduced by contact isolation efficacy FIG. 1. General tree structure.
1692 Clinical Microbiology and Infection, Volume 17 Number 11, November 2011 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1691–1697
Sponge screening involved wiping the upper arm and thigh
on both sides over an area of approximately 5 inches. Swab
screening consisted of rubbing two sites, the buccal mucosa
and groin, covering a 2 · 2 area, each with a new swab [15].
Both screening strategies involved a 48-h time delay to
account for technician time and the incubation period
required for both tests, during which time A. baumannii
patients could freely transmit the infection to other patients.
Each simulation run sent 1000 ICU patients through the
model 1000 times (1 000 000 total trials). To compare
screening strategies, we compared the distribution of incre-
mental costs of implementing a screening strategy with no
screening strategy.
Total costscreening  Total costno screening
Additional analyses examined how this incremental cost
differed among strategies.
Data inputs
Table 1 lists the parameters used with their corresponding
distributions and sources. Distributions in the model (e.g.
LOS) represent the diversity of possible A. baumannii infection
severity. Screening costs included the cost of materials and
the time needed by the technician to process the sample and
results. The contact isolation cost included the cost of gloves
and gowns and additional nursing time (approximately 1 min)
spent donning and removing them for each patient contact a
day. A 3% discount rate converted all costs to 2010 $US.
Sensitivity analyses
Sensitivity analyses explored the effects of varying key param-
eters such as A. baumannii colonization prevalence (range:
0.5–4%, based on observation and expert opinion), probabil-
ity of infection given colonization (range, 30–70%, as it has
not been clearly established) [8,23,24], A. baumannii LOS (10,
15 and 20 days, and LOS distribution) [2,5,8,11,21], R (range,
0.25–1.0) and contact isolation efﬁcacy (range, 25–75%).
Additionally, probabilistic sensitivity analyses simultaneously
varied all parameters over the ranges listed in Table 1.
Results
Cost of an A. baumannii case
Initial simulations determined the cost of an A. baumannii
case (colonized or infected) to the hospital with varying
probabilities of infection: 30% probability of infection,
$80 503 (standard deviation (SD), $30 410); 40% probability
of infection, $84 989 (SD, $34 100); 50% probability of infec-
tion, $93 133 (SD, $36 239); 60% probability of infection,
$96 777 (SD, $36 037); and 70% probability of infection,
$104 141 (SD, $40 272). The additional cost came from the
increased LOS of A. baumannii infections that translated into
lost bed days.
Sponge screening
Table 2 shows the incremental cost-savings of implementing
sponge screening compared with no screening (LOS distribu-
tion); negative values represent cost-savings, bold values
indicates screening was always cost-saving. Although the con-
ﬁdence intervals (CIs) crossed zero in many of the scenarios,
the median values were consistently negative, meaning that
sponge screening was cost-saving in a majority of replica-
tions. Sponge screening was predominantly cost-saving for
nearly all scenarios tested. The exception was when the
probability of A. baumannii colonization was £1%, probability
of infection £30%, contact isolation efﬁcacy £25% and
R £ 0.25, in which case, the cost was £$2. Even at a low
TABLE 1. Model input parameters
Variable
Distribution
type Mean
Range (standard
deviation) Source
Costs (US$)
Sponge 2.50 [15]
Swab 1 Expert opinion
mLAM plate 1 Expert opinion
Gloves (pair) 0.0836 [29]
Gowns 0.8955 [29]
Bed days in ICU Triangular 4397.50 1000–8000 [30]
Nurse wage (median) Triangular 31.57 21.77–46.40 [31]
Technician wage (median) Triangular 17.84 11.80–27.35 [31]
Durations
Time delay (h) 48 [15]
Time process sample (min) 10 Expert opinion
Time don/remove (min) 1 [29]
Length of stay (days) Gamma 26.67 5.30 [5,11,21]
Number patient contacts per day Uniform 25–50 [32]
Probabilities
Sponge sensitivity Beta 83.4 2.71 [15]
Swab sensitivity Beta 58.3 15.2 [15]
Speciﬁcity of screening Uniform 98–100 Expert opinion
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contact isolation efﬁcacy (25%), cost-savings ranged from
)$1 to )$524 per ICU admission screening. As shown in
Table 2, the median cost-savings ranged from )$50 to
)$1225 with 75% efﬁcacious contact isolation. The 95% CI
fell completely below zero when R ‡ 1 for several coloniza-
tion rates, signifying that sponge screening was always
cost-saving compared with no screening (Table 2, bold
values). If the probability of A. baumannii colonization was
reduced to 0.5%, savings ranged from )$2 (R = 0.25, contact
isolation 25%, and probability of infection 70%) to )$134
(R = 1, contact isolation 75%, probability of infection 60%).
Varying LOS showed little effect on results; when contact
isolation was ‡75% efﬁcacious, sponge screening cost-saving
ranged from )$24 to )$311, )$32 to )$493 and )$61 to
)$681 for 10, 15 and 20-day LOS, respectively. For 1500
ICU admissions, sponge screening could potentially save
‡$189 095 (contact isolation ‡75%, R ‡ 0.5, colonization
prevalence ‡1%, probability of infection ‡50%).
Swab screening
Table 2 also shows the incremental cost-savings of imple-
menting swab screening vs. no screening, where negative val-
ues represent cost-savings and bold values indicate screening
was always cost-saving. Again, the CIs cross zero, but median
values are negative, implying cost-savings in a majority of rep-
lications. Swab screening was predominantly cost-saving for
nearly all scenarios tested, except when A. baumannii coloni-
zation was £1%, probability of infection £40%, contact isola-
tion efﬁcacy £25% and R £ 0.25, in which case, the cost was
£$3. Median cost-savings ranged from )$33 to )$855 per
ICU admission screening with 75% efﬁcacious contact isola-
tion. The 95% CIs were entirely below zero at R = 1, ‡4%
colonization rate and ‡60% probability of infection, suggest-
ing that swab screening was always cost-saving compared
with no screening. At 0.5% A. baumannii colonization rate,
savings ranged from )$4 (R = 0.5, contact isolation 25%,
probability of infection 50%) to )$95 (R = 1, contact isola-
tion 75%, probability of infection 60%). Swab screening was
not cost-saving at any probability of infection when contact
isolation was £25% and R = 0.25. LOS had little effect; with
contact isolation efﬁcacy ‡75%, cost-savings ranged from
)$14 to )$214, )$19 to )$340 and )$46 to )$490 for 10,
15 and 20-day LOS, respectively. For 1500 ICU admissions,
swab screening could potentially save ‡$129 472 (when con-
tact isolation ‡75%, R ‡ 0.5, colonization prevalence ‡1%,
probability of infection ‡50%).
Sponge vs. swab screening
Table 3 shows the cost-savings comparing the two screening
methods. In almost every scenario tested, sponge screening
was more cost-saving than swab screening. The exception
was when colonization rate was £1% and probability of infec-
tion £30%, for every R value and contact isolation efﬁcacy
tested. Under these conditions, swab screening was more
TABLE 2. Incremental cost-savings
of implementing screening vs. no
screening (contact isolation efﬁ-
cacy of 75%; LOS distribution)
Acinetobacter
baumannii
colonization
Probability of infection (%)
30 40 50 60
Sponge screening
Reproductive ratea = 0.25
2% )50 ()354, 287) )82 ()439, 248) )119 ()460, 211) )151 ()489, 202)
3% )86 ()480, 259) )124 ()550, 268) )191 ()592, 260) )232 ()672, 224)
4% )116 ()561, 298) )172 ()679, 326) )244 ()784, 244) )312 ()839, 215)
Reproductive ratea = 0.5
2% )122 ()436, 167) )176 ()553, 147) )248 ()671, 95) )307 ()807, 104)
3% )187 ()592, 160) )279 ()706, 159) )353 ()918, 96) )455 ()1096, 12)
4% )269 ()769, 134) )375 ()946, 126) )505 ()1256, 7) )596 ()1403, 8)
Reproductive ratea = 1
2% )253 ()668, 66) )361 ()915, 35) 2469 (21148, 246) 2601 (21394, 2136)
3% )370 ()907, 52) 2527 (21271, 29) 2750 (21711, 269) 2963 (22048, 2247)
4% 2520 (21204, 234) 2735 (21629, 2102) 21003 (22172, 2214) 21225 (22707, 2365)
Swab screening
Reproductive ratea = 0.25
2% )33 ()339, 303) )57 ()411, 291) )80 ()426, 273) )109 ()464, 274)
3% )60 ()463, 320) )89 ()510, 342) )136 ()539, 318) )163 ()613, 296)
4% )79 ()526, 341) )117 ()610, 389) )167 ()658, 316) )219 ()760, 297)
Reproductive ratea = 0.5
2% )85 ()388, 243) )129 ()521. 232) )175 ()563, 209) )213 ()653, 230)
3% )135 ()539, 263) )197 ()639, 240) )239 ()795, 227) )325 ()910, 151)
4% )193 ()722, 241) )271 ()845, 238) )351 ()1068, 171) )415 ()1165, 206)
Reproductive ratea = 1
2% )175 ()569, 151) )249 ()769, 174) )323 ()1003, 118) )408 ()1130, 49)
3% )267 ()771, 171) )361 ()1068, 142) )549 ()1489, 116) )667 ()1707, 19)
4% )365 ()1003, 148) )527 ()1324, 133) )680 ()1847, 46) )855 (22186, 218)
Note: median (95% conﬁdence interval); negative values represent cost-savings; bold values represent screening was
always cost-saving.
aReproductive rate = number of new cases one infectious individual generates.
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cost-saving (savings £$1.50). Additional cost-savings of
sponge screening increased as the probability of colonization,
probability of infection, R, and contact isolation efﬁcacy
increased. Cost-savings ranged from )$9 to )$421 at con-
tact isolation ‡75%, showing that sponge screening can save
more than swab screening. For a majority of scenarios
tested, swab screening cost between $2 and $3 more than
sponge screening. The CIs never fell below zero for any sce-
nario tested when comparing sponge vs. swab screening.
Annual savings
There are approximately 4.4 million ICU admissions annually
in the United States [25,26]. Extrapolating to annual cost-sav-
ings across the US (contact isolation ‡75%, R ‡ 0.5), univer-
sal sponge screening could save ‡$231 million, whereas swab
screening could save ‡$138 million (1% colonization rate,
30% probability of infection). A 3% colonization rate and
50% probability of infection lead to savings of £$1.6 billion
(sponge screening). Savings increased with annual ICU admis-
sions. For 900 and 2000 ICU admissions, savings were
‡$77 683 and ‡$172 629, respectively (colonization ‡1%,
‡50% probability of infection), for both screening methods.
Discussion
A. baumannii is an increasingly important healthcare-associ-
ated antibiotic-resistant pathogen. However, less is known
about the economic value of an active screening programme
targeting this pathogen, compared with other pathogens (e.g.
MRSA). Our results suggest that screening ICU admissions
for A. baumannii could help hospitals reduce a hidden source
of costs. Even slight increases in ICU LOS can be quite
expensive to hospitals. Finding an intervention to be poten-
tially cost-saving strongly supports its adoption. While both
screening methods can result in various degrees of cost-
savings, depending on the local colonization rate, the sponge
method brings higher sensitivity for not much more added
cost. This higher sensitivity is likely to stem from the fact
that the sponge sweeps over larger areas of the skin,
whereas swab screening only catches select targeted areas.
To date, studies of A. baumannii surveillance have been
limited and few have evaluated universal active screening
[27,28]. The Johns Hopkins Hospital has implemented uni-
versal surveillance for multidrug-resistant (MDR) A. bauman-
nii in admissions to their medical intensive and intermediate
care units [27]. Surveillance involved culturing axillae,
wounds, sputum and endotracheal tube aspirations and test-
ing these cultures for antibiotic susceptibility, which demon-
strated that four of eight newly identiﬁed patients with
MDR A. baumannii were identiﬁed by surveillance cultures
alone [27]. Low admission prevalence and the need to pro-
cess a large number of samples led the authors to conclude
that active surveillance should be limited to either outbreak
situations or high-risk populations [27]. However, this study
did not explicitly evaluate the overall cost-beneﬁt of screen-
ing. Moreover, the low reported sensitivity of the swab
screening method, especially when conducted without an
enrichment process, may have led to an underestimation of
the true number of cases [15,16]. A Thai ICU study evalu-
ated active A. baumannii surveillance as one facet of a multi-
faceted intervention and found favourable results for
screening [28]. Surveillance, along with enhanced contact
isolation precautions, cohorting and enhanced environmen-
tal cleaning, decreased the long-term incidence of pandrug-
resistant A. baumannii colonization and infection, as well as
treatment costs and overall hospitalization. However, the
study could not isolate the effect of surveillance from the
other interventions.
Modelling can help when data are limited, as in the case
of A. baumannii. Because infections typically occur in criti-
cally ill patients, it can be challenging to separate A. bauman-
TABLE 3. Incremental cost-savings
of implementing sponge screening
compared with swab screening
(contact isolation efﬁcacy of 75%;
LOS distribution)
Acinetobacter baumannii
colonization
Probability of infection (%)
30 40 50 60
Reproductive ratea = 0.25
2% )11 ()73, 3) )18 ()115, 3) )25 ()129, 2) )35 ()166, 2)
3% )22 ()112, 3) )28 ()141, 3) )47 ()191, 2) )57 ()233, 2)
4% )27 ()129, 3) )43 ()189, 3) )62 ()276, 2) )78 ()317, 2)
Reproductive ratea = 0.5
2% )29 ()155, 3) )39 ()219, 3) )57 ()303, 2) )74 ()375, 2)
3% )44 ()225, 3) )68 ()309, 3) )94 ()368, 2) )114 ()442, 2)
4% )58 ()283, 3) )87 ()383, 3) )124 ()511, 2) )157 ()618, 2)
Reproductive ratea = 1
2% )55 ()320, 3) )84 ()453, 3) )115 ()578, 2) )160 ()635, 2)
3% )86 ()482, 3) )124 ()586, 3) )178 ()817, 2) )233 ()969, 2)
4% )129 ()586, 3) )181 ()763, 2) )245 ()1076, 2) )317 ()1243, 2)
Note: median (95% conﬁdence interval); negative values represent cost-savings.
aReproductive rate = number of new cases one infectious individual generates.
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nii’s impact from patients’ co-morbidities. Models can dem-
onstrate how data uncertainty can affect outcomes and
which results hold despite this uncertainty. For example,
our model showed that active screening can continue to
save hospital costs across a wide range of scenarios, even
at low colonization prevalence, which is fairly compelling
evidence favouring its implementation. Modelling can also
help identify important data needs and guide future clinical
and epidemiological studies. Future studies may focus on
elucidating colonization prevalence, the probability of infec-
tion and the probability of various clinical outcomes from
A. baumannii infection, as all could drive the value of
screening.
Our model may in fact underestimate the potential cost-
savings of screening. We only considered lost bed days and
did not include other potential costs to the hospital, such as
increased personnel and other resource (e.g. ventilators)
demands that may not come with concomitant increases in
reimbursement. Furthermore, the model focused on how
identifying carriers early can reduce spread but not on how
it may lead to earlier implementation of appropriate antibiotic
treatment for those who progress from colonization to
infection, thus potentially resulting in better treatment out-
comes and reduced stays. These latter potential beneﬁts are
still under debate. Moreover, the advantage of selective
media to distinguish MDR from non-MDR A. baumannii iso-
lates is unclear. Finally, active surveillance could provide valu-
able information to hospitals, helping to better understand
A. baumannii’s epidemiology and bolster other control mea-
sures. Because our model focused on direct costs from the
hospital perspective, it did not include death from A. bauman-
nii; however, prevented deaths would be another beneﬁt of
screening.
Although other studies have evaluated the cost-effective-
ness of screening for MRSA in various hospitalized popula-
tions [17–20], the unique characteristics of A. baumannii
necessitate an A. baumannii-speciﬁc study. Patients infected
with A. baumannii tend to be on average more critically ill.
A. baumannii alone appears to have different effects on hospi-
tal LOS and requires different resources.
Limitations
Computer models cannot represent every possible A. bau-
mannii event or outcome and are therefore, simpliﬁcations
of real life. Our model used data pulled from disparate data
from a limited number of studies of varying quality. The
generalizability of our results is unknown as sponge screen-
ing is relatively novel and has not been validated or tested
in other locations and the sensitivity of both methods
depended on the use of mLAM, which may not be readily
available. Also, it is unclear whether the number of patients
under contact isolation precautions has an effect on health-
care worker adherence (these effects were not included in
this model).
Conclusion
Universal A. baumannii screening of patients entering the ICU
may help hospitals save costs over a wide range of circum-
stances, even at low carriage rates. Sponge screening may be
more cost-saving than swab screening, but either method
could provide economic value. These results favour the
implementation of active ICU screening at hospitals depend-
ing on the local epidemiology.
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